Deutsche Bank Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Market Context

Denali Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $22.52 with a market capitalization of $2.5B. The stock has gained 56.7% over the past 52 weeks.

Analyst coverage from Deutsche Bank provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Denali Therapeutics Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Denali Therapeutics Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 16, 2026	Deutsche Bank	Buy	N/A
Jul 13, 2026	JP Morgan	Overweight	N/A
May 26, 2026	Morgan Stanley	Overweight	N/A
May 14, 2026	Morgan Stanley	Overweight	N/A
May 11, 2026	BTIG	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View DNLI Stock Page